Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + lapatinib
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination of cabazitaxel and lapatinib that was investigated for the treatment of HER2-positive metastatic breast cancer with central nervous system (CNS) metastases. Cabazitaxel is a second-generation semisynthetic taxane that stabilizes microtubules and can cross the blood-brain barrier. Lapatinib is a small molecule tyrosine kinase inhibitor targeting both EGFR and HER2 receptors that also crosses the blood-brain barrier.
02
Targets
MicrotubuleERBB2 (Erb-b2 receptor tyrosine kinase 2)ABCB1 (P-glycoprotein)ABCG2 (Breast cancer resistance protein)
Beyond the preview
Go deeper on cabazitaxel + lapatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + lapatinib.